All the sessions from Transform 2021 are available on-demand now. Watch now.
- H-P “great-grandchild” Alverix raises $7.7M for portable diagnostic devices (release)
- Moksha8 takes in $39M to commercialize drugs for Asia (peHUB)
- Dynogen Pharma goes public, gets $98M in reverse merger (release)
- EKR Thera raises funds, pays up to $170M to “reacquire” PDL BioPharma drug (release))
- R4 Vascular receives $4.4M for vascular-access devices (VentureWire)
- Medical tube and syringe maker Amsino Medical sells stake to Baring PE Asia (release)
- Implantable-diagnostic maker Transoma Medical postpones IPO (IPOhome)
H-P “great-grandchild” Alverix raises $7.7M for portable diagnostic devices — I’ve moved this item to a standalone post here.
EKR Thera raises funds, pays up to $170M to “reacquire” PDL BioPharma drug — This item is now a standalone post here.
Moksha8 takes in $39M to commercialize drugs for Asia — Moksha8, a stealthy San Francisco drug developer that commercializes “high-value” therapies for Asia and other markets, raised a combined $39 million in first and second funding rounds, peHUB reports, citing regulatory filings. TPG Biotech provided the $24 million first round, and was joined by Lit Tele of Brazil in a $15 million second round.
Actually, I call Moksha8 a San Francisco company because peHUB does, but I have my doubts. The company’s stub of a Web site lists offices in Hong Kong, SF, Philadelphia and London, and provides Hong Kong and Philadelphia-area phone numbers as its main points of contact. The company’s name, by the way, appears to be a reference to the Hindu term for liberation from the cycle of reincarnation. One more observation from the Web site: Moksha8’s “other markets” are likely in Central and South America, which is the only region besides Asia highlighted on a global-map background image there.
Dynogen Pharma goes public, gets $98M in reverse merger — Dynogen Pharmaceuticals, a Waltham, Mass., specialty pharma focused on gastrointestinal disease, went public in a reverse merger with Apex Bioventures Acquisition, a “specialty acquisition” corporation. Such entities are formed by investors specifically to acquire private companies, and frequently — as in this case — raise funds for later acquisitions via an IPO.
Dynogen shareholders will receive $98 million in Apex stock, and are eligible for two additional milestone-related payments of $23 million apiece. The combined company, which will be run by Dynogen’s CEO and operate out of Dynogen’s current offices, is expected to have up to $65 million in cash by the time the deal closes.
Implantable-diagnostic maker Transoma Medical postpones IPO — Transoma Medical, a St. Paul, Minn., maker of implantable medical-diagnostic devices, postponed its planned $77.6 million IPO, IPOhome reports. The company hasn’t yet formally withdrawn the offering, although that seems a foregone conclusion at this point.
Transoma makes implantable monitoring devices, such as a wireless gadget that monitors an individual’s heartbeat and transmits the information to a data center and then to a doctor’s office. Our previous coverage of Transoma is here and here; we’ve also written about startups working on similar devices, such as CardioMEMS and its implantable wireless sensors for measuring blood pressure, heart function and heart rate, here.
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more